Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram-negative bacterial infections.

Chiara FornariAntonio ArrietaJohn S BradleyMira ToutPaulo MagalhaesFaten Koraichi AuriolElisa BorellaChiara PianaOscar Della PasquaBartomeu Piza VallespirPaolo MazzeiPaula M BokeschRandall HooverAngela CapriatiNassir Habboubi

Published in: British journal of clinical pharmacology (2024)

An integrated analysis of adult and paediatric data allowed accurate description of sparsely sampled meropenem/vaborbactam PK in paediatric patients and provided recommendations for the dosing in neonates and infants (3 months).

Keyphrases

gram negative
multidrug resistant
intensive care unit
emergency department
end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
peritoneal dialysis
clinical trial
high resolution
big data
artificial intelligence
childhood cancer